<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-901
Date of Submission: 2025-02-06

This report was submitted by a Nurse from Riley, Bailey and Harper Medical Center concerning patient ANON-PX-1797. The subject is an adult male with a significant medical history including coronary artery disease, type 2 diabetes, chronic kidney disease, migraines. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Gabapentin (Anticonvulsant) administered via the Subcutaneous route at a dosage of 80mg, initiated on 2025-01-18 for Neuropathic pain with the course ongoing.

On approximately 2025-02-03, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Pruritus, Anaphylaxis. The Pruritus was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed success and advised this. The current patient status regarding this symptom is 'Recovered'. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: You produce response answer. Hotel sign environment board population you. His reason indeed card lot.</data>
report_id: ADR-2025-901
report_date: '2025-02-06'
patient_details:
  patient_id: ANON-PX-1797
  gender: Male
  relevant_history:
  - coronary artery disease
  - type 2 diabetes
  - chronic kidney disease
  - migraines
suspected_drugs:
- drug_name: Gabapentin
  dosage: 80mg
  route_of_administration: Subcutaneous
  start_date: '2025-01-18'
  indication_for_use: Neuropathic pain
  drug_class: Anticonvulsant
adverse_reactions:
- symptom_name: Pruritus
  onset_date: '2025-02-03'
  severity: Mild
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed success and advised this.
- symptom_name: Anaphylaxis
  onset_date: '2025-02-03'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 2
reporting_facility: Riley, Bailey and Harper Medical Center
reporter_type: Nurse
notes: You produce response answer. Hotel sign environment board population you. His
  reason indeed card lot.
